z-logo
Premium
Characterization of Mouse DAF on Transfectant Cells Using Monoclonal Antibodies Which Recognize Different Epitopes
Author(s) -
Ohta Rieko,
Imai Masaki,
Fukuoka Yoshihiro,
Miwa Takashi,
Okada Noriko,
Okada Hidechika
Publication year - 1999
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.1999.tb01234.x
Subject(s) - decay accelerating factor , chinese hamster ovary cell , biology , gene isoform , microbiology and biotechnology , transfection , complement system , epitope , hamster , complementary dna , monoclonal antibody , alternative splicing , cell culture , antibody , gene , biochemistry , immunology , genetics
Several membrane proteins prevent host cells from homologous complement attack. In humans, one such protein, decay‐accelerating factor (DAF), exists as two isoforms, a GPI anchored form and a secreted form, which are generated by alternative splicing. DAF in mouse is also expressed as two isoforms, a GPI anchored form (GPI‐DAF) and a transmembrane form (TM‐DAF), which are produced from two separate genes. In this study, we transfected cDNA of mouse GPI‐DAF or TM‐DAF into Chinese hamster ovary (CHO) cells. Both isoforms of DAF on CHO cells were shown to regulate mouse complement C3 deposition mediated by the classical and alternative pathways and the inhibitory activity of both isoforms was species restricted. The two mouse DAF isoforms were effective against rat complement but not against human and guinea pig complement. Furthermore, we produced hamster mAbs to mouse DAF using GPI‐DAF transfectant cells and established seven unique mAbs (RIKO‐1–7). Western blotting analysis using RIKO‐3, which reacts with both GPI‐DAF and TM‐DAF, and RIKO‐4, which is an anti‐GPI‐DAF specific mAb, indicated that GPI‐DAF was expressed on erythrocytes, spleen and testis, and that TM‐DAF was expressed only in testis.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here